LANCL2 - Landos
Landos has identified Lanthionine Synthetase C-Like 2 (LANCL2) as a novel therapeutic target for autoimmune diseases, including inflammatory bowel disease (IBD); Crohn’s disease (CD) and ulcerative colitis (UC). Based on extensive preclinical studies, Landos has validated a unique mechanism of action involving LANCL2 that exerts potent anti-inflammatory effects with an outstanding safety profile.
- Pharmacological activation of LANCL2 by BT-11 intercepts IBD at two levels:
- Increasing anti-inflammatory markers such as IL-10 and FOXP3.
- Decreasing pro-inflammatory markers, like IFNγ, MCP-1 and TNFα. The latter is a molecular target by standard-of-care therapies for IBD such as anti-TNF biologics.
- Landos Biopharma is developing first-in-class molecules that strongly bind to LANCL2, with an oral route of administration, and have potent anti-inflammatory effects in the gastrointestinal (GI) tract.
- The Landos technology includes composition of matter claims protecting BT-11, 48 privileged scaffolds, and 3 billion compounds (USPT 9,556,146).
- In addition to the lead indication for IBD, the Landos technology includes both method of use and composition of matter claims for IBD, diabetes (type 1 and 2), and influenza-related lung inflammation.
LANCL2: A technology that translates into the human setting
The Landos team has performed human translational studies in blood cells from Crohn’s disease patients. Our results demonstrate that Landos’ preclinical findings translate to humans since BT-11, our LANCL2-binding small molecule for IBD, increases anti-inflammatory molecules, such as IL-10 and FOXP3, and decreased pro-inflammatory markers, such as MCP1, TNFα, and IFNγ in human immune cells.